| Date | Time | Source | Headline | Symbol | Company |
| 07/03/2024 | 1:00PM | iHub Newswire | FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent | | |
| 07/27/2023 | 7:25AM | IH Market News | Thursday’s Wall Street Highlights: Salesforce, Mattel, Shell, Meta, McDonald’s, and more | NYSE:ABBV | AbbVie Inc |
| 07/26/2023 | 9:00AM | PR Newswire (US) | AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets | NYSE:ABBV | AbbVie Inc |
| 07/26/2023 | 8:05AM | PR Newswire (US) | SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 4:30PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 7:55AM | Dow Jones News | AbbVie's Rinvoq Drug Gets Health Canada Green Light | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 7:00AM | PR Newswire (Canada) | Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis | NYSE:ABBV | AbbVie Inc |
| 07/25/2023 | 7:00AM | PR Newswire (Canada) | AbbVie reçoit l'approbation de Santé Canada pour l'emploi de RINVOQ® (upadacitinib) dans le traitement des adultes atteints de colite ulcéreuse modérément à fortement évolutive | NYSE:ABBV | AbbVie Inc |
| 07/24/2023 | 8:05AM | PR Newswire (US) | AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa | NYSE:ABBV | AbbVie Inc |
| 07/21/2023 | 4:30AM | PR Newswire (US) | AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NYSE:ABBV | AbbVie Inc |
| 07/20/2023 | 3:09PM | Dow Jones News | AbbVie on Pace for Largest Percent Increase Since June 2022 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 07/17/2023 | 7:30AM | IH Market News | Monday’s Wall Street Highlights: Microsoft, Santander, Tesla, Chewy, and more | NYSE:ABBV | AbbVie Inc |
| 07/10/2023 | 5:04PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NYSE:ABBV | AbbVie Inc |
| 07/06/2023 | 4:18PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:ABBV | AbbVie Inc |
| 07/06/2023 | 8:00AM | PR Newswire (US) | AbbVie to Host Second-Quarter 2023 Earnings Conference Call | NYSE:ABBV | AbbVie Inc |
| 06/29/2023 | 5:00PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:ABBV | AbbVie Inc |
| 06/28/2023 | 5:01PM | Edgar (US Regulatory) | Annual Report of Employee Stock Plans (11-k) | NYSE:ABBV | AbbVie Inc |
| 06/28/2023 | 5:00PM | Edgar (US Regulatory) | Form 11-K - Annual report of employee stock purchase, savings and similar plans | NYSE:ABBV | AbbVie Inc |
| 06/27/2023 | 7:48PM | Dow Jones News | AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment | NYSE:ABBV | AbbVie Inc |
| 06/27/2023 | 6:50PM | PR Newswire (US) | AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) | NYSE:ABBV | AbbVie Inc |
| 06/26/2023 | 8:00AM | PR Newswire (US) | AbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally | NYSE:ABBV | AbbVie Inc |
| 06/23/2023 | 8:58AM | Dow Jones News | AbbVie Gets Positive CHMP Opinion For Migraine Treatment | NYSE:ABBV | AbbVie Inc |
| 06/23/2023 | 8:04AM | PR Newswire (US) | AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine | NYSE:ABBV | AbbVie Inc |
| 06/22/2023 | 1:13PM | PR Newswire (US) | AbbVie Declares Quarterly Dividend | NYSE:ABBV | AbbVie Inc |
| 06/15/2023 | 8:45AM | PR Newswire (US) | Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients | NYSE:ABBV | AbbVie Inc |
| 06/13/2023 | 8:45AM | PR Newswire (US) | BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program | NYSE:ABBV | AbbVie Inc |
| 06/09/2023 | 4:03PM | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NYSE:ABBV | AbbVie Inc |
| 06/09/2023 | 10:39AM | Dow Jones News | NY AG Lands Final Approval for $17.3 Billion Opioid Settlement | NYSE:ABBV | AbbVie Inc |
| 06/09/2023 | 3:00AM | PR Newswire (US) | AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients | NYSE:ABBV | AbbVie Inc |
| 06/07/2023 | 7:01AM | PR Newswire (Canada) | AbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program | NYSE:ABBV | AbbVie Inc |